Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 14 publications
Exploratory analyses of predictors and correlates of response to omalizumab therapy in patients with multiple food allergies.
Journal: The Journal of allergy and clinical immunology
Published: April 28, 2025
Tocilizumab and remdesivir in hospitalized patients with severe COVID-19 pneumonia: a randomized clinical trial.
Journal: Intensive care medicine
Published: July 13, 2021
Lysophosphatidic acid species are associated with exacerbation in chronic obstructive pulmonary disease.
Journal: BMC pulmonary medicine
Published: February 18, 2021
A randomized, placebo-controlled trial evaluating effects of lebrikizumab on airway eosinophilic inflammation and remodelling in uncontrolled asthma (CLAVIER).
Journal: Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology
Published: March 30, 2020
Phase 2 trial to assess lebrikizumab in patients with idiopathic pulmonary fibrosis.
Journal: The European respiratory journal
Published: December 18, 2019
Seasonal variability of lung function and Asthma Quality of Life Questionnaire Scores in adults with uncontrolled asthma.
Journal: BMJ open respiratory research
Published: April 11, 2019
Serum periostin levels in adults of Chinese descent: an observational study.
Journal: Allergy, asthma, and clinical immunology : official journal of the Canadian Society of Allergy and Clinical Immunology
Published: August 23, 2018
Model-based clinical pharmacology profiling and exposure-response relationships of the efficacy and biomarker of lebrikizumab in patients with moderate-to-severe asthma.
Journal: Pulmonary pharmacology & therapeutics
Published: May 05, 2017
Seasonal variability of severe asthma exacerbations and clinical benefit from lebrikizumab.
Journal: The Journal of allergy and clinical immunology
Published: September 13, 2016
Efficacy and safety of lebrikizumab in patients with uncontrolled asthma (LAVOLTA I and LAVOLTA II): replicate, phase 3, randomised, double-blind, placebo-controlled trials.
Journal: The Lancet. Respiratory medicine
Published: July 22, 2016
Last Updated: 09/26/2026